Discovering you have an ovarian cyst can be a source of anxiety, even though these fluid-filled sacs are extremely common. For many women, cysts are painless and go unnoticed, discovered only during a routine exam. However, for others, they can cause pelvic pain, bloating, and a sense of heaviness that interferes with daily comfort. The uncertainty of whether a cyst will grow, rupture, or resolve on its own can be stressful.

Treatment is essential to manage symptoms and, in some cases, prevent the formation of future cysts. While most cysts are “functional”, meaning they are part of the normal menstrual cycle and often disappear on their own, others may require intervention to prevent complications like torsion (twisting of the ovary) or rupture. Because cysts vary widely in type and size, treatment plans are highly individualized. Doctors consider a woman’s age, symptoms, and reproductive goals before recommending a course of action (Office on Women’s Health, 2021).

Overview of treatment options for Ovarian Cysts

The approach to treating ovarian cysts often begins with “watchful waiting.” Since many functional cysts resolve spontaneously within a few menstrual cycles, doctors frequently monitor the cyst via ultrasound rather than intervening immediately. When medical treatment is required, the primary goals are pain management and the prevention of new cysts.

Medications are typically used to control symptoms and regulate hormones. It is important to clarify that while medication can prevent new cysts from forming, it generally does not speed up the disappearance of existing cysts. Surgical procedures are usually reserved for cysts that are large, look suspicious on imaging, or cause severe, persistent pain that does not respond to medication.

Medications used for Ovarian Cysts

Hormonal contraceptives are the cornerstone of preventative therapy for recurrent functional cysts. Doctors frequently prescribe combined oral contraceptives (birth control pills), as well as patches or vaginal rings. These medications regulate the menstrual cycle and are the most effective non-surgical method for preventing the development of new cysts. Clinical experience suggests that women who use hormonal birth control have a significantly lower risk of developing functional ovarian cysts compared to those who do not.

For symptom relief, non-steroidal anti-inflammatory drugs (NSAIDs) are the standard first-line treatment. Over-the-counter options like ibuprofen or naproxen are commonly used to alleviate the pelvic discomfort and cramping associated with cysts.

In rare cases where cysts are related to a more complex condition like endometriosis, doctors may prescribe gonadotropin-releasing hormone (GnRH) agonists. These drugs induce a temporary menopause-like state to stop the ovaries from functioning for a short period, though they are not typically used for simple functional cysts. Patients can expect rapid pain relief from NSAIDs, while the preventative benefits of hormonal therapy become established over the course of a few menstrual cycles (Mayo Clinic, 2023).

How these medications work

Hormonal contraceptives work by suppressing ovulation. Functional cysts, such as follicular cysts and corpus luteum cysts, form during the normal process of releasing an egg. By introducing steady levels of estrogen and progestin, these medications stop the ovaries from producing eggs. If ovulation does not occur, the functional cysts associated with it cannot form.

NSAIDs work by inhibiting the body’s production of prostaglandins. These are chemical messengers that promote inflammation, pain, and uterine contractions. By blocking these chemicals, NSAIDs reduce the sensitivity of pelvic nerves and decrease the dull ache or sharp pains often caused by the cyst pressing on surrounding tissues (National Institutes of Health, 2022).

Side effects and safety considerations

Hormonal birth control is generally safe but may cause side effects like nausea, breast tenderness, mood changes, and spotting. It carries a small, increased risk of blood clots, especially in smokers or women over 35, for which doctors screen carefully.

NSAIDs can irritate the stomach, causing heartburn or ulcers if taken often or on an empty stomach. Long-term use requires monitoring of kidney function. Severe, sudden abdominal pain with fever or vomiting needs immediate emergency care, as it may signal a ruptured or twisted cyst requiring urgent surgery.

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. Mayo Clinic. https://www.mayoclinic.org
  2. Office on Women’s Health. https://www.womenshealth.gov
  3. National Institutes of Health. https://www.nih.gov
  4. American College of Obstetricians and Gynecologists. https://www.acog.org

Medications for Ovarian Cysts

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Ovarian Cysts.

Found 1 Approved Drug for Ovarian Cysts

Citrtae

Brand Names
MiloPhene, Clomid

Citrtae

Brand Names
MiloPhene, Clomid
Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome, amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS.) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below: 1. Patients who are not pregnant. 2. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. 3. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. 4. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: 1. Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. 2. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. 3. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. 4. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. 5. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses.
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances